Mortality associated with the development of acute liver failure after a single dose of nivolumab

[1]  Y. Kodera,et al.  Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies , 2021, Hepatology International.

[2]  Lindsey N Teal,et al.  Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma , 2021, Case reports in oncological medicine.

[3]  P. Bindal,et al.  Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[4]  M. Yeh,et al.  Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. , 2019, Seminars in diagnostic pathology.

[5]  M. Oyama,et al.  Delayed nivolumab‐induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case , 2019, IJU case reports.

[6]  E. Konishi,et al.  Fulminant hepatitis as an immune‐related adverse event after nivolumab treatment , 2019, Pathology international.

[7]  Matthew J. Frigault,et al.  Management of Immunotherapy-Related Toxicities, Version 1.2019. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[9]  D. Samuel,et al.  Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. , 2018, Journal of hepatology.

[10]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Yeh,et al.  Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury , 2018, Modern Pathology.

[12]  L. Siu,et al.  Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.